ArticleTherapeutic advances in musculoskeletal disease2013
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis.
Article in Therapeutic advances in musculoskeletal disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2017Guideline
- Fabrication techniques and biomedical applications of strontium-based nanofibers.Journal of nanobiotechnology · 2026Review
- The calcium-sensing receptor: a comprehensive review on its role in calcium homeostasis and therapeutic implications.American journal of translational research · 2025Review
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- Apatite/Chitosan Composites Formed by Cold Sintering for Drug Delivery and Bone Tissue Engineering Applications.Nanomaterials (Basel, Switzerland) · 2024Article
- Insights into the Mechanism of Osteoporosis and the Available Treatment Options.Current pharmaceutical biotechnology · 2024Review
- Pain Management in Osteoporosis.Indian journal of orthopaedics · 2023Article
- Aerogel-Based Materials in Bone and Cartilage Tissue Engineering-A Review with Future Implications.Gels (Basel, Switzerland) · 2023Review
- Managing Early Onset Osteoporosis: The Impact of Premature Ovarian Insufficiency on Bone Health.Journal of clinical medicine · 2023Review
- Review
- The role of TNFRSF11B in development of osteoarthritic cartilage.Rheumatology (Oxford, England) · 2022Article
- Influence of systemic strontium ranelate on the progression and as adjunctive therapy for the nonsurgical treatment of experimental periodontitis.Journal of clinical and experimental dentistry · 2021Article
- Synthesis and characterization of silver substituted strontium phosphate silicate apatite using solid-state reaction for osteoregenerative applications.Bioengineered · 2021Article
- Advances in Osteoporotic Bone Tissue Engineering.Journal of clinical medicine · 2021Review
- Facilitated and Controlled Strontium Ranelate Delivery Using GCS-HA Nanocarriers Embedded into PEGDA Coupled with Decortication Driven Spinal Regeneration.International journal of nanomedicine · 2021Article
- Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.BioMed research international · 2021Article
- Functionality-packed additively manufactured porous titanium implants.Materials today. Bio · 2020Article
- Effect of inferior alveolar nerve transection on the inorganic component of bone of rat mandible.Journal of musculoskeletal & neuronal interactions · 2020Article
- Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.Frontiers in cell and developmental biology · 2020Review
- The Impact of Long-and Short-Term Strontium Treatment on Metabolites and Minerals inMolecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic fractures are one of the major causes of increased morbidity and mortality in postmenopausal women and the overall aging population. One of the major issues in the management of postmenopausal osteoporosis is to find a safe and effective treatment in the long term (>3 years) to achieve and maintain a reduction in the risk of fracture. Strontium ranelate (PROTELOS(®)) is a relatively novel drug, currently approved in Europe for the treatment of postmenopausal osteoporosis. Strontium ranelate is the first agent of a new therapeutic class in osteoporosis, capable of both promoting bone formation and, to a lesser extent, inhibiting bone resorption. This uncoupling in bone turnover results in a net gain in bone mineral density (BMD), bone quality improvement and reduction in risk of vertebral and nonvertebral fractures, as initially demonstrated in the preplanned long-term registrative trials SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment of Peripheral Osteoporosis) at 5 years. Recently, open-label extensions of the SOTI and TROPOS trials up to 8 and, recently, 10 years have confirmed the sustained efficacy of strontium ranelate in increasing BMD, the long-term safety profile and the high compliance to treatment, independently from baseline BMD or other risk factors for osteoporotic fractures. Recent economic impact analyses have proved that long-term treatment with strontium ranelate is highly cost effective, especially in women older than 70 years of age. Histomorphometric analyses in animals and humans participating in the phase III trials have proved that the quality of mineralization is preserved in the long term and bone microarchitecture is ameliorated, with increased bone strength. Thus, strontium ranelate has been confirmed to be an effective compound for the long-term, chronic treatment of postmenopausal osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.